By acquiring Switzerland-based Sensile Medical AG in July this year, Gerresheimer is expanding its business model to become an original equipment manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities. Sensile Medical develops innovative drug delivery products and platforms, including digital connective functions, for pharmaceutical and biopharmaceutical customers. The company will be joining Gerresheimer’s team of experts and sales specialists at CPhI Worldwide in Madrid for the first time.

“Pooling Gerresheimer’s and Sensile Medical’s expertise is an ideal move for any of our customers looking for innovation,” says Sandra de Haan, Chief Business Officer at Sensile. Sensile Medical’s leading position in micro pump technology combined with drug delivery devices featuring electronic and connected capabilities for medical applications is progressing to market readiness in specific customer projects with pharma companies. Sensile Medical is involved with pharma companies in the early stages of drug and therapy development. The company is to become the Development Division, covering the field of innovative devices for the entire Gerresheimer Group. It is already working very successfully on projects with customers to develop devices for diabetics and patients with heart disease.

The micro rotary piston pump – a key component

Sensile Medical AG developed a new kind of micro pump, which is the key component of all products. SenseCore is small, very precise in dosage, and inexpensive to manufacture as it is only made up of two plastic parts. Thanks to its high degree of flexibility, it is compatible with a variety of drugs. It is the key component in a range of pump platforms. Sensile Medical’s current product range stands out thanks to its high dosage accuracy, easy handling, and safe drug delivery mechanisms.

Gerresheimer will be presenting all of these products at booth 4C30 at CPhI, hosted by the IFEMA congress and events center in Madrid.

More information: Sensile Medical – a Gerresheimer company

 

Über die Gerresheimer AG

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With our plants in Europe, North America, South America, and Asia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Firmenkontakt und Herausgeber der Meldung:

Gerresheimer AG
Klaus-Bungert-Straße 4
40468 Düsseldorf
Telefon: +49 (211) 6181-00
Telefax: +49 (211) 6181-295
http://www.gerresheimer.de

Ansprechpartner:
Marion Stolzenwald
Senior Manager Corporate Communication
Telefon: +49 (211) 6181-246
Fax: +49 (211) 6181-28246
E-Mail: m.stolzenwald@gerresheimer.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.